Biofrontera Biofrontera
  1. Biofrontera
  2. Investors & Media
  3. Financial announcements

Latest News Releases

No news available.

Financial announcements archive

2025

PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST NINE MONTHS OF 2025

PTA-News: Biofrontera AG: Biofrontera AG signs an agreement with Propharma d.o.o. for the distribution of Ameluz® in Croatia

PTA-News: Biofrontera AG: Biofrontera AG completes sale of U.S. Ameluz® and RhodoLED® assets to Biofrontera Inc.

PTA-News: Biofrontera AG: Correction notice regarding the H1 2025 report and the corresponding press release dated September 30, 2025, 00:18 a.m.

PTA-News: Biofrontera AG: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST HALF OF 2025

PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST HALF OF 2025

PTA-Adhoc: Biofrontera AG: Expected impairment losses

PTA-Adhoc: Biofrontera AG: Biofrontera AG: New Forecast

PTA-Adhoc: Biofrontera AG: Biofrontera Inc. Fulfills the conditions for implementing the term sheet with Biofrontera AG

PTA-News: Biofrontera AG: Secures Long-Term U.S. Market Presence Through Strategic Restructuring Agreement with Biofrontera Inc.

PTA-Adhoc: Biofrontera AG: Agreement with Biofrontera Inc. about cooperation in the future

PTA-Adhoc: Biofrontera AG: EXTENSION OF BIOFRONTERA INC. PAYMENT DEFERRAL - UPDATE

PTA-Adhoc: Biofrontera AG: Extension of Biofrontera Inc. payment deferral - update

PTA-Adhoc: Biofrontera AG: BIOFRONTERA AG IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA INC.

PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST QUARTER OF 2025

PTA-Adhoc: Biofrontera AG: Payment Difficulties of Biofrontera Inc. and Recall of Outlook

PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FINANCIAL YEAR 2024

PTA-Adhoc: Biofrontera AG: DISCLOSURE OF INSIDE INFORMATION PURSUANT TO ARTICLE 17 MAR

2024

PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST NINE MONTHS OF 2024

PTA-News: Biofrontera AG: ADJUSTMENT OF THE FORECAST FOR THE FINANCIAL YEAR 2024

PTA-News: Biofrontera AG: Biofrontera announces agreement with Galenica AB for the promotion and distribution of Ovixan® in the United Kingdom

PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST HALF OF 2024

PTA-News: Biofrontera AG: Successful Annual General Meeting with broad approval and new Supervisory Board members

PTA-News: Biofrontera AG: Biofrontera announces agreement with LEO Pharma Germany for the promotion of Advantan® and Skinoren®

PTA-Adhoc: Biofrontera AG: Legal dispute on import in the USA and resulting revised outlook

PTA-News: Biofrontera AG: Biofrontera hosted CME-Certified Training "Photodynamic Therapy (PDT) at the Cutting Edge" in Berlin

PTA-News: Biofrontera AG: Biofrontera AG announces the registration of the capital increase

PTA-Adhoc: Biofrontera AG: Biofrontera AG reports result of the capital increase resolved on April 04, 2024

PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST QUARTER OF 2024

PTA-News: Biofrontera AG: Biofrontera strategically on course for growth; Realignment of the Supervisory Board

PTA-News: Biofrontera AG: Biofrontera executes capital reduction and capital increase

PTA-Adhoc: Biofrontera AG: CHANGES IN THE SUPERVISORY BOARD

PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FINANCIAL YEAR 2023

PTA-Adhoc: Biofrontera AG: Biofrontera AG resolves capital increase from authorized capital

PTA-News: Biofrontera AG: Biofrontera transfers clinical research to the U.S.

PTA-Adhoc: Biofrontera AG: Biofrontera AG announces revised strategy

PTA-News: Biofrontera AG: Biofrontera and GME enter into a cooperation to promote the MultiLite® daylight lamp for PDT treatment

PTA-Adhoc: Biofrontera AG: Biofrontera AG plans capital reduction and considers subsequent capital increase from authorized capital

PTA-News: Biofrontera AG: Ameluz® obtains approval extension for use with artificial daylight in the EU and the UK

PTA-News: Biofrontera AG: EMA approves an optimized formulation of Ameluz®

PTA-News: Biofrontera AG: EMA recommends Ameluz® label extension for actinic keratosis treatment with artificial daylight

2022

PTA-News: Biofrontera AG: Commercial launch of Ameluz® in Finland

PTA-News: Biofrontera AG: Biofrontera establishes UK subsidiary to strengthen its sales activities in the country

PTA-News: Biofrontera AG: Biofrontera reports on business development in the third quarter and the first nine months of 2022

PTA-Adhoc: Biofrontera AG: Biofrontera is going to submit proposal for resolution on capital increase at an extraordinary shareholders' meeting

PTA-News: Biofrontera AG: Biofrontera AG strengthens international marketing and sales activities

PTA-Adhoc: Biofrontera AG: Biofrontera AG reports result of the capital increase resolved on April 07, 2022

PTA-News: Biofrontera AG: Subscription offer for up to 7,089,673 new shares begins on October 28, 2022

PTA-Adhoc: Biofrontera AG: Higher Regional Court of Cologne grants release of the capital increase

PTA-News: Biofrontera AG: Biofrontera AG obtains notice of allowance for U.S. patent on nanoemulsion formulation

PTA-News: Biofrontera AG: Annual General Meeting of Biofrontera AG appoints Prof. Dr. Karin Lergenmüller as a member of the Supervisory Board

PTA-Adhoc: Biofrontera AG: Exclusion of the Maruho Deutschland GmbH from today's Annual General Meeting

PTA-Adhoc: Biofrontera AG: Appointment of Mrs Pilar de la Huerta Martinez as new Chief Financial Officer

PTA-News: Biofrontera AG: Biofrontera extends appointment of Management Board member Paul Böckmann

PTA-News: Biofrontera AG: Biofrontera reports financial results for the six months ended June 30, 2022

PTA-Adhoc: Biofrontera AG: Dismissal of Chief Financial Officer Ludwig Lutter for cause

PTA-News: Biofrontera AG: The request to convene an extraordinary shareholders' meeting by Maruho is not complied with

PTA-News: Biofrontera AG: Maruho Deutschland GmbH demands convening of an extraordinary general meeting

PTA-News: Biofrontera AG: Employees appeal in own statement to the shareholders not to accept the takeover offer of Deutsche Balaton AG

PTA-Adhoc: Biofrontera AG: Major shareholders submit competing election proposals for elections to the Supervisory Board

PTA-News: Biofrontera AG: Management Board and Supervisory Board jointly recommend not to accept the takeover offer of Deutsche Balaton AG

PTA-News: Biofrontera AG: Biofrontera AG will publish statement on takeover offer by Deutsche Balaton AG shortly

PTA-News: Biofrontera AG: Biofrontera obtains notice of allowance for Australian patent on innovative PDT treatment protocol

PTA-Adhoc: Biofrontera AG: Supervisory Board of Biofrontera AG appoints Paul Böckmann to the Management Board

PTA-News: Biofrontera AG: Biofrontera's license partner Louis Widmer receives an extension of its marketing authorization for Ameluz®

PTA-Adhoc: Biofrontera AG: Biofrontera AG will terminate its U.S. ADS program

PTA-News: Biofrontera AG: Biofrontera reports results for the first quarter of 2022

PTA-News: Biofrontera AG: First quarter conference call to be held on May 19, 2022

PTA-News: Biofrontera AG: Biofrontera reports results for the fiscal year 2021

PTA-Adhoc: Biofrontera AG: Biofrontera AG specifies its guidance for the financial year 2022

PTA-News: Biofrontera AG: Biofrontera shifts the publication of the Annual Report 2021 to April 29, 2022

PTA-News: Biofrontera AG: Biofrontera announces conference call to be held on April 29, 2022 to discuss fiscal year 2021 financial results

PTA-Adhoc: Biofrontera AG: Biofrontera announces first preliminary unaudited results for fiscal year 2021 and financial guidance for 2022

PTA-News: Biofrontera AG: Governmental price decree for Ameluz® withdrawn in Spain

PTA-News: Biofrontera AG: Statement of Biofrontera AG on the open letter of Maruho Deutschland GmbH dated March 31, 2022

PTA-News: Biofrontera AG: Biofrontera improves the brand protection of Ameluz®-PDT in the US and strengthens internal quality assurance structures

PTA-News: Biofrontera AG: Biofrontera files Form 15F to suspend SEC Reporting Requirements and starts trading Level I ADS program on US OTC market

PTA-Adhoc: Biofrontera AG: Biofrontera is going to submit proposals for resolutions on capital measures at an extraordinary shareholders' meeting

PTA-Adhoc: Biofrontera AG: Changes in the supervisory board

PTA-Adhoc: Biofrontera AG: Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs

PTA-News: Biofrontera AG: Biofrontera AG announces progress of phase III study for the treatment of sBCC with Ameluz®

PTA-Adhoc: Biofrontera AG: Biofrontera announces preliminary revenue figures for the full year 2021

2021

PTA-Adhoc: Biofrontera AG: Biofrontera AG announces reduction of shareholding in Biofrontera Inc. below 50%

PTA-News: Biofrontera AG: Biofrontera AG announces results of the elections for the new Supervisory Board

PTA-News: Biofrontera AG: Biofrontera enrolls first patient to phase IIb clinical study evaluating Ameluz® / BF-RhodoLED® for acne

PTA-News: Biofrontera AG: Biofrontera AG obtains notice of allowance for US patent on PDT-lamp and treatment method

PTA-News: Biofrontera AG: Biofrontera enrolls first patient to phase I safety study evaluating photodynamic therapy with three tubes of Ameluz®

PTA-News: Biofrontera AG: Biofrontera obtains notice of allowance for US patent on innovative illumination protocol

PTA-Adhoc: Biofrontera AG: Biofrontera AG announces timing of the departure of the CEO

PTA-Adhoc: Biofrontera AG: Biofrontera Inc. announces closing of USD15 million private placement

PTA-Adhoc: Biofrontera AG: Biofrontera Inc. announces USD15 million private placement

PTA-Adhoc: Biofrontera AG: Biofrontera reaches out-of-court settlement with DUSA Pharmaceuticals, Inc.

PTA-Adhoc: Biofrontera AG: Biofrontera AG announces mediation results

PTA-News: Biofrontera AG: Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021

PTA-News: Biofrontera AG: Biofrontera AG announces initiation of clinical studies

PTA-Adhoc: Biofrontera AG: CEO seeks early retirement from the Management Board

PTA-News: Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021

PTA-Adhoc: Biofrontera AG: Early repayment of EIB loan

PTA-News: Biofrontera AG: Biofrontera is setting the path for further expansion in the U.S. with the IPO of its US subsidiary Biofrontera Inc.

PTA-Adhoc: Biofrontera AG: Biofrontera Inc. closes IPO

PTA-Adhoc: Biofrontera AG: Initial public offering price of Biofrontera Inc. IPO

PTA-Adhoc: Biofrontera AG: Biofrontera AG approves modification of the US-IPO of Biofrontera Inc.

PTA-Adhoc: Biofrontera AG: Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp

PTA-Adhoc: Biofrontera AG: Biofrontera AG approves IPO of Biofrontera Inc. in the USA

PTA-News: Biofrontera AG: Biofrontera reports preliminary approximate revenues for the month of September 2021

PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of August 2021

PTA-News: Biofrontera AG: Biofrontera reports financial results for the six months ended June 30, 2021

PTA-News: Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021

PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of July 2021

PTA-News: Biofrontera AG: Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland

PTA-Adhoc: Biofrontera AG: Biofrontera Inc. seeks IPO in the USA

PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of June 2021

PTA-News: Biofrontera AG: Biofrontera provides update on clinical developments

PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of May 2021

PTA-News: Biofrontera AG: Biofrontera reports Q1 2021 financial results

PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of April 2021

PTA-News: Biofrontera AG: First quarter conference call to be held on May 12, 2021

PTA-News: Biofrontera AG: Biofrontera reports results for the 2020 financial year

PTA-News: Biofrontera AG: Biofrontera announces preliminary revenue for Q1 2021

PTA-News: Biofrontera AG: Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results

PTA-News: Biofrontera AG: Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lamp

PTA-News: Biofrontera AG: Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million

PTA-News: Biofrontera AG: Biofrontera AG announces entry of capital increase into the commercial register

PTA-News: Biofrontera AG: Biofrontera submits study report of pharmacokinetics study to FDA

PTA-Adhoc: Biofrontera AG: Biofrontera AG announces results of the capital increase resolved on May 28, 2020 - Gross proceeds of EUR 24.7 million

PTA-Adhoc: Biofrontera AG: Biofrontera AG announces subscription price of new shares from capital increase resolved on May 28, 2020

PTA-Adhoc: Biofrontera AG: Details of the capital increase resolved on May 28, 2020 - Subscription period begins February 08, 2021

PTA-News: Biofrontera AG: Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021

PTA-Adhoc: Biofrontera AG: Biofrontera announces preliminary revenue figures for the full year 2020

PTA-Adhoc: Biofrontera AG: Cologne Higher Regional Court grants approval of capital increase

Financial announcements